百利天恒：镥-BL-ARC001注射液获临床试验批准

Core Viewpoint - The company has received formal approval from the National Medical Products Administration (NMPA) for the clinical trial of its innovative drug BL-ARC001, marking a significant milestone in its research and development efforts in the field of antibody-radionuclide conjugates (ARC) [1] Group 1 - The clinical trial approval pertains to the company's self-developed innovative drug BL-ARC001 injection [1] - BL-ARC001 is the company's first Class I innovative drug in the ARC field [1] - The drug is noted to have completely independent intellectual property rights and is a potential first-in-class ARC drug globally [1]